;PMID: 6589638
;source_file_2885.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..50] = [t:0..50]
;1)sentence:[e:56..193] = [t:56..193]
;2)section:[e:197..259] = [t:197..259]
;3)sentence:[e:263..439] = [t:263..439]
;4)sentence:[e:440..570] = [t:440..570]
;5)sentence:[e:571..716] = [t:571..716]
;6)sentence:[e:717..917] = [t:717..917]
;7)sentence:[e:918..1108] = [t:918..1108]
;8)sentence:[e:1109..1249] = [t:1109..1249]
;9)sentence:[e:1250..1370] = [t:1250..1370]
;10)section:[e:1374..1418] = [t:1374..1418]

;section 0 Span:0..50
;Proc Natl Acad Sci U S A.  1984 Aug;81(15):4940-4.
(SEC
  (FRAG (NNP:[0..4] Proc) (NNP:[5..9] Natl) (NNP:[10..14] Acad)
        (NNP:[15..18] Sci) (NNP:[19..20] U) (NNP:[21..22] S) (NNP:[23..24] A)
        (.:[24..25] .) (CD:[27..31] 1984) (::[32..36] Aug;) (CD:[36..38] 81)
        (-LRB-:[38..39] -LRB-) (CD:[39..41] 15) (-RRB-:[41..42] -RRB-)
        (::[42..43] :) (CD:[43..47] 4940) (CD:[47..50] -4.)))

;sentence 1 Span:56..193
;Enhanced expression of the human gene N-myc consequent to amplification of
;DNA  may contribute to malignant progression of neuroblastoma.
;[94..99]:gene-rna:"N-myc"
;[114..127]:variation-type:"amplification"
;[179..192]:malignancy-type:"neuroblastoma"
(SENT
  (S-HLN
    (NP-SBJ
      (NP (VBN:[56..64] Enhanced) (NN:[65..75] expression))
      (PP (IN:[76..78] of)
        (NP
          (NP (DT:[79..82] the) (JJ:[83..88] human) (NN:[89..93] gene))
          (NP (NN:[94..99] N-myc))))
      (ADJP (JJ:[100..110] consequent)
        (PP (TO:[111..113] to)
          (NP
            (NP (NN:[114..127] amplification))
            (PP (IN:[128..130] of)
              (NP (NN:[131..134] DNA)))))))
    (VP (MD:[136..139] may)
      (VP (VB:[140..150] contribute)
        (PP-CLR (TO:[151..153] to)
          (NP
            (NP (JJ:[154..163] malignant) (NN:[164..175] progression))
            (PP (IN:[176..178] of)
              (NP (NN:[179..192] neuroblastoma)))))))
    (.:[192..193] .)))

;section 2 Span:197..259
;Schwab M, Ellison J, Busch M, Rosenau W, Varmus HE, Bishop JM.
(SEC
  (FRAG (NNP:[197..203] Schwab) (NNP:[204..206] M,) (NNP:[207..214] Ellison)
        (NNP:[215..217] J,) (NNP:[218..223] Busch) (NNP:[224..226] M,)
        (NNP:[227..234] Rosenau) (NNP:[235..236] W) (,:[236..237] ,)
        (NNP:[238..244] Varmus) (NNP:[245..247] HE) (,:[247..248] ,)
        (NNP:[249..255] Bishop) (NNP:[256..258] JM) (.:[258..259] .)))

;sentence 3 Span:263..439
;Previous studies had revealed that DNA with partial similarity to the myc 
;oncogene (N-myc) is frequently amplified in human neuroblastoma cell lines
;and  neuroblastoma tumors.
;[333..336]:gene-rna:"myc"
;[348..353]:gene-rna:"N-myc"
;[369..378]:variation-type:"amplified"
;[388..401]:malignancy-type:"neuroblastoma"
;[418..438]:malignancy-type:"neuroblastoma tumors"
(SENT
  (S
    (NP-SBJ (JJ:[263..271] Previous) (NNS:[272..279] studies))
    (VP (VBD:[280..283] had)
      (VP (VBN:[284..292] revealed)
        (SBAR (IN:[293..297] that)
          (S
            (NP-SBJ
              (NP (NN:[298..301] DNA))
              (PP (IN:[302..306] with)
                (NP
                  (NP (JJ:[307..314] partial) (NN:[315..325] similarity))
                  (PP (TO:[326..328] to)
                    (NP
                      (NP (DT:[329..332] the) (NN:[333..336] myc)
                          (NN:[338..346] oncogene))
                      (PRN (-LRB-:[347..348] -LRB-) (NN:[348..353] N-myc)
                           (-RRB-:[353..354] -RRB-)))))))
            (VP (VBZ:[355..357] is)
              (ADVP-TMP (RB:[358..368] frequently))
              (VP (VBN:[369..378] amplified)
                (PP (IN:[379..381] in)
                  (NP
                    (NP (JJ:[382..387] human) (NN:[388..401] neuroblastoma)
                        (NN:[402..406] cell) (NNS:[407..412] lines))
                    (CC:[413..416] and)
                    (NP-LOC (NN:[418..431] neuroblastoma)
                            (NNS:[432..438] tumors))))))))))
    (.:[438..439] .)))

;sentence 4 Span:440..570
;We show here for one patient that N-myc amplification is  confined to the
;neuroblastoma tumor and is not present in normal tissue.
;[474..479]:gene-rna:"N-myc"
;[480..493]:variation-type:"amplification"
;[514..533]:malignancy-type:"neuroblastoma tumor"
(SENT
  (S
    (NP-SBJ (PRP:[440..442] We))
    (VP (VBP:[443..447] show)
      (ADVP (RB:[448..452] here))
      (PP (IN:[453..456] for)
        (NP (CD:[457..460] one) (NN:[461..468] patient)))
      (SBAR (IN:[469..473] that)
        (S
          (NP-SBJ-1 (NN:[474..479] N-myc) (NN:[480..493] amplification))
          (VP
            (VP (VBZ:[494..496] is)
              (VP (VBN:[498..506] confined)
                (NP-1 (-NONE-:[506..506] *))
                (PP (TO:[507..509] to)
                  (NP (DT:[510..513] the)
                     (NN:[514..527] neuroblastoma) (NN:[528..533] tumor)))))
            (CC:[534..537] and)
            (VP (VBZ:[538..540] is) (RB:[541..544] not)
              (ADJP-PRD (JJ:[545..552] present))
              (PP-LOC (IN:[553..555] in)
                (NP (JJ:[556..562] normal) (NN:[563..569] tissue))))))))
    (.:[569..570] .)))

;sentence 5 Span:571..716
;N-myc  mRNA approximately equal to 4.0 kilobases in size is detectable in
;neuroblastoma  cell lines and tumors and in a retinoblastoma cell line.
;[571..576]:gene-rna:"N-myc"
;[645..658]:malignancy-type:"neuroblastoma"
;[691..705]:malignancy-type:"retinoblastoma"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[571..576] N-myc) (NN:[578..582] mRNA))
      (ADJP (RB:[583..596] approximately) (JJ:[597..602] equal)
        (PP (TO:[603..605] to)
          (NP
            (NP (CD:[606..609] 4.0) (NNS:[610..619] kilobases))
            (PP (IN:[620..622] in)
              (NP (NN:[623..627] size)))))))
    (VP (VBZ:[628..630] is)
      (ADJP-PRD (JJ:[631..641] detectable))
      (PP
        (PP (IN:[642..644] in)
          (NP
            (NP
              (NML-1 (NN:[645..658] neuroblastoma))
              (NN:[660..664] cell) (NNS:[665..670] lines))
            (CC:[671..674] and)
            (NP
              (NML-1 (-NONE-:[674..674] *P*))
              (NNS:[675..681] tumors))))
        (CC:[682..685] and)
        (PP (IN:[686..688] in)
          (NP (DT:[689..690] a) (NN:[691..705] retinoblastoma)
              (NN:[706..710] cell) (NN:[711..715] line)))))
    (.:[715..716] .)))

;sentence 6 Span:717..917
;By contrast,  appreciable amounts of this RNA were not present in a number of
;cell lines  derived from other human tumors and in fibroblasts from a normal
;individual and  from a neuroblastoma patient.
;[895..908]:malignancy-type:"neuroblastoma"
(SENT
  (S
    (PP (IN:[717..719] By)
      (NP (NN:[720..728] contrast)))
    (,:[728..729] ,)
    (NP-SBJ
      (NP (JJ:[731..742] appreciable) (NNS:[743..750] amounts))
      (PP (IN:[751..753] of)
        (NP (DT:[754..758] this) (NN:[759..762] RNA))))
    (VP (VBD:[763..767] were)
      (VP (RB:[768..771] not)
        (ADJP-PRD (JJ:[772..779] present))
        (PP
          (PP (IN:[780..782] in)
            (NP
              (NP (DT:[783..784] a) (NN:[785..791] number))
              (PP (IN:[792..794] of)
                (NP
                  (NP (NN:[795..799] cell) (NNS:[800..805] lines))
                  (VP (VBN:[807..814] derived)
                    (NP (-NONE-:[814..814] *))
                    (PP (IN:[815..819] from)
                      (NP (JJ:[820..825] other) (JJ:[826..831] human)
                          (NNS:[832..838] tumors))))))))
          (CC:[839..842] and)
          (PP-LOC (IN:[843..845] in)
            (NP
              (NP (NNS:[846..857] fibroblasts))
              (PP
                (PP (IN:[858..862] from)
                  (NP (DT:[863..864] a) (JJ:[865..871] normal)
                      (NN:[872..882] individual)))
                (CC:[883..886] and)
                (PP (IN:[888..892] from)
                  (NP (DT:[893..894] a) (NN:[895..908] neuroblastoma)
                      (NN:[909..916] patient)))))))))
    (.:[916..917] .)))

;sentence 7 Span:918..1108
;Low levels of N-myc RNA were found in human and  murine neuroblastoma cell
;lines lacking amplification of this gene, up to  80-fold greater levels in
;all cell lines carrying amplified N-myc.
;[932..937]:gene-rna:"N-myc"
;[974..987]:malignancy-type:"neuroblastoma"
;[1007..1020]:variation-type:"amplification"
;[1092..1101]:variation-type:"amplified"
;[1102..1107]:gene-rna:"N-myc"
(SENT
  (S
    (NP-SBJ-1
      (NP (JJ:[918..921] Low) (NNS:[922..928] levels))
      (PP (IN:[929..931] of)
        (NP (NN:[932..937] N-myc) (NN:[938..941] RNA))))
    (VP (VBD:[942..946] were)
      (VP (VBN:[947..952] found)
        (NP-1 (-NONE-:[952..952] *))
        (PP (IN:[953..955] in)
          (NP
            (NP
              (NP (JJ:[956..961] human)
                (NML-2 (-NONE-:[961..961] *P*)))
              (CC:[962..965] and)
              (NP (JJ:[967..973] murine)
                (NML-2 (NN:[974..987] neuroblastoma) (NN:[988..992] cell)
                       (NNS:[993..998] lines))))
            (VP (VBG:[999..1006] lacking)
              (NP
                (NP (NN:[1007..1020] amplification))
                (PP (IN:[1021..1023] of)
                  (NP (DT:[1024..1028] this) (NN:[1029..1033] gene)))))))
        (,:[1033..1034] ,)
        (NP-ADV
          (NP
            (ADJP
              (NML
                (QP (RB:[1035..1037] up) (TO:[1038..1040] to)
                    (CD:[1042..1044] 80))
                (HYPH:[1044..1045] -) (RB:[1045..1049] fold))
              (JJR:[1050..1057] greater))
            (NNS:[1058..1064] levels))
          (PP (IN:[1065..1067] in)
            (NP
              (NP (DT:[1068..1071] all) (NN:[1072..1076] cell)
                  (NNS:[1077..1082] lines))
              (VP (VBG:[1083..1091] carrying)
                (NP (VBN:[1092..1101] amplified) (NN:[1102..1107] N-myc))))))))
    (.:[1107..1108] .)))

;sentence 8 Span:1109..1249
;In situ  hybridization to sections of neuroblastoma tumors revealed high
;expression of  N-myc predominantly in undifferentiated neuroblasts.
;[1147..1167]:malignancy-type:"neuroblastoma tumors"
;[1197..1202]:gene-rna:"N-myc"
(SENT
  (S
    (NP-SBJ
      (NP
        (ADJP (FW:[1109..1111] In) (FW:[1112..1116] situ))
        (NN:[1118..1131] hybridization))
      (PP (TO:[1132..1134] to)
        (NP
          (NP (NNS:[1135..1143] sections))
          (PP (IN:[1144..1146] of)
            (NP (NN:[1147..1160] neuroblastoma) (NNS:[1161..1167] tumors))))))
    (VP (VBD:[1168..1176] revealed)
      (NP
        (NP (JJ:[1177..1181] high) (NN:[1182..1192] expression))
        (PP (IN:[1193..1195] of)
          (NP (NN:[1197..1202] N-myc))))
      (PP-LOC
        (ADVP (RB:[1203..1216] predominantly))
        (IN:[1217..1219] in)
        (NP (JJ:[1220..1236] undifferentiated) (NNS:[1237..1248] neuroblasts))))
    (.:[1248..1249] .)))

;sentence 9 Span:1250..1370
;We hypothesize that  amplification and consequent elevated expression of
;N-myc may be related to  malignant progression.
;[1271..1284]:variation-type:"amplification"
;[1323..1328]:gene-rna:"N-myc"
(SENT
  (S
    (NP-SBJ (PRP:[1250..1252] We))
    (VP (VBP:[1253..1264] hypothesize)
      (SBAR (IN:[1265..1269] that)
        (S
          (NP-SBJ-1
            (NP
              (NP (NN:[1271..1284] amplification))
              (CC:[1285..1288] and)
              (NP (JJ:[1289..1299] consequent) (VBN:[1300..1308] elevated)
                  (NN:[1309..1319] expression)))
            (PP (IN:[1320..1322] of)
              (NP (NN:[1323..1328] N-myc))))
          (VP (MD:[1329..1332] may)
            (VP (VB:[1333..1335] be)
              (VP (VBN:[1336..1343] related)
                (NP-1 (-NONE-:[1343..1343] *))
                (PP-CLR (TO:[1344..1346] to)
                  (NP (JJ:[1348..1357] malignant) (NN:[1358..1369] progression)))))))))
    (.:[1369..1370] .)))

;section 10 Span:1374..1418
;PMID: 6589638 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1374..1378] PMID) (::[1378..1379] :) (CD:[1380..1387] 6589638)
        (NN:[1388..1389] -LSB-) (NNP:[1389..1395] PubMed) (::[1396..1397] -)
        (NN:[1398..1405] indexed) (IN:[1406..1409] for)
        (NNP:[1410..1418] MEDLINE-RSB-)))
